#USA #New York #Multiple Myeloma #AI Market Intelligence #Medisights

Medisights Unleashes AI to Transform Market Intelligence in Complex Diseases

In a groundbreaking development, Medisights, an innovative platform focused on life sciences, has successfully demonstrated a revolutionary approach to market research through AI technology. On September 16, 2026, the company announced the completion of a landmark study revealing that purpose-built AI agents can effectively navigate the complexities of Multiple Myeloma, collecting actionable market intelligence at an unprecedented scale.

Multiple Myeloma, known for its intricate landscape and rapidly evolving treatment practices, has historically posed significant challenges for traditional market research methods. These conventional approaches tend to take months to gather insights, leaving life sciences companies with outdated information. Medisights aims to address this gap by drastically reducing research timelines to mere days and weeks, thereby offering real-time market intelligence that enables organizations to react swiftly to changes in the marketplace.

Accelerating Research with AI

The major question driving this study was: “Can AI keep us up-to-date with deep information on innovative practices and near-real-time developments in the Multiple Myeloma landscape?” The results were conclusive. Medisights' innovative AI moderators conducted deep, adaptive conversations with medical specialists that often lasted between 45 to 60 minutes. These exchanges were designed to capture the intricate reasoning behind physicians' prescribing behaviors and map the referral patterns for CAR-T therapies as they develop.

The AI agents were uniquely designed to foster natural and engaging interactions, overcoming the hurdles often encountered by traditional market researchers who struggle to secure extended interviews with physicians due to time constraints or lack of engagement.

Key Findings from the Study

The insights gathered from Medisights' groundbreaking research unlock actionable strategies for life sciences organizations:

1. Insurance Navigation: The study pinpointed insurance authorization as a significant barrier for the adoption of in vivo CAR-T therapies, highlighting a critical area for improvement.
2. Addressing Knowledge Gaps: There is a pronounced misunderstanding among community oncologists regarding the distinction between in vivo CAR-T therapies and other products. This underscores the necessity for targeted medical education to clarify the differences in treatment modalities.
3. Value Proposition of Treatment-Free Intervals: Results revealed that minimizing manufacturing wait times could significantly enhance treatment-free intervals, positioning “speed-to-treatment” as a key narrative for in vivo therapies compared to bispecifics.
4. Benchmarking Efficacy Expectations: A correlation between the clinical adoption of therapies and established benchmarks for ex vivo products (like MRD negativity rates and overall survival metrics) was established.

A Future-Forward Approach

CEO Frank Seo articulated the vision of Medisights, stating, “Imagine a world where you have AI acting as a real-time intelligence layer, continuously engaging with specialists to keep you informed on innovative practices as they unfold.” This innovative approach is set to revolutionize how life sciences companies track and respond to shifts in the market, especially concerning complex diseases like Multiple Myeloma.

Unlike generic AI platforms, Medisights' unique agents are designed with a deep understanding of advanced clinical taxonomies, ensuring utmost accuracy and fidelity to clinical facts. This guarantees that life sciences teams have access to reliable information tailored to their specific needs.

Conclusion: Redefining Market Research

Medisights is not just reshaping how market research is conducted, but is also enhancing the overall strategic approach of pharmaceutical companies. By deploying AI-driven workflows, the company has transformed stagnant reports into dynamic insights, fostering an environment of compliance and traceability tailored for intricate therapeutic markets.

For additional information about Medisights and its innovative methodologies, visit Medisights' website.